Prosecution Insights
Last updated: November 04, 2026
Application No. 18/026,964

COMPOSITION FOR TREATING OR PREVENTING DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH ENDOPLASMIC RETICULUM STRESS OR ALL-TRANS-RETINAL, PROTECTING RETINAL THICKNESS, OR SUPPRESSING REDUCTION IN RETINAL THICKNESS OR PROGRESS OF REDUCTION IN RETINAL THICKNESS

Final Rejection §102§112§DOUBLEPATENT
Filed
Mar 17, 2023
Priority
Sep 17, 2020 — JP 2020-156757 +1 more
Examiner
CHANDRA, GYAN
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Restore Vision Inc.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
721 granted / 1012 resolved
+11.2% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
38 currently pending
Career history
1051
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
31.7%
-8.3% vs TC avg
§102
15.0%
-25.0% vs TC avg
§112
30.6%
-9.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1012 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response filed on 8/27/2026 is acknowledged and fully considered. Status of Application, Amendments, And/Or Claims The amendments of claim 63, 67-68, and 72-73, and the addition of claims 83-84 have been made of record. Claims 64-66, 69-71 and 74-82 are cancelled. Claims 63, 67-68,72-73 and 83-84 are pending and under consideration. Drawings Applicant’s filing of New corrected drawings in compliance with 37 CFR 1.121(d) are acknowledged and fully considered. Claim Rejections - 35 USC § 102-withdrawn The rejection of claim(s) 63-73 under 35 U.S.C. 102(a)(1) as being anticipated by Kurihara et al. (IDS, WO 2020/148913) is withdrawn in view of applicants’ amendments to claims 63, 67-68, and 72-73 and the cancellation of claims 64-66, 69-71 and 74-82. Additionally, applicants’ arguments that Kurihara is available for less than one year has been found persuasive Claim Rejections - 35 USC § 112-scope of enablement-maintained The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 63, 67-68,72-73 remain rejected and newly added claims 83-84 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating a retinal disease in a subject in need thereof comprising administering an effective amount of a light absorbing substance wherein the substance is a chimeric rhodopsin, does not reasonably provide enablement for a method of preventing retinal disease in a subject in need thereof comprising an effective amount of any light absorbing substance. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Applicants argue that they have now amended the claims to a method of treating or preventing a retinal disease in a subject in need thereof comprising administering an effective amount of a light absorbing substance to the subject and therefore, it would be allowable. Applicants’ arguments have been fully considered but they are not persuasive because the claims now read on “preventing any retinal disease” comprising administering an effective amount of a light absorbing substance to the subject which is not enabled because the specification only enabled for a method of treating but not preventing any retinal disease. Applicant may want to delete the term “preventing” to overcome with the rejection. Double Patenting-withdrawn The rejection of claims 63-65, 70-71 and 73 on the ground of nonstatutory double patenting as being unpatentable over claims 1,12 and 14-16 of U.S. Patent No. 11,771,741 is withdrawn in view of applicant’s amendments to claim 63 and the cancellation of claims 64-65, 70-71. The provisional rejection of claims 63-65, and 67-73 on the ground of nonstatutory double patenting as being unpatentable over claims 43-49, and 51 of copending Application No. 19239,026 is withdrawn in view of applicant’s amendments to claim 63 and the cancellation of claims 64-65, 70-71. The provisional rejection of claims 63-65, 68-71 and 73 on the ground of nonstatutory double patenting as being unpatentable over claims 1, 7, 13, 19, 26, 28, 33-36 of copending Application No. 17/642,923 is withdrawn in view of applicant’s amendments to claim 63 and the cancellation of claims 64-65, 70-71. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GYAN CHANDRA whose telephone number is (571)272-2922. The examiner can normally be reached Mon-Friday 8:30AM-5:00P. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GYAN CHANDRA/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Mar 17, 2023
Application Filed
Apr 27, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT
Aug 27, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780892
LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE
3y 11m to grant Granted Nov 03, 2026
Patent 12779036
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
3y 4m to grant Granted Nov 03, 2026
Patent 12767697
GIP AND GLP-1 DUAL AGONIST POLYPEPTIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT AND APPLICATION THEREOF
4y 6m to grant Granted Oct 20, 2026
Patent 12760082
GROWTH HORMONE FUSION PROTEIN AND PREPARATION METHOD AND USE THEREOF
3y 7m to grant Granted Oct 13, 2026
Patent 12742000
INSULIN-FC FUSION PROTEINS AND METHODS OF USE TO TREAT CANCER
3y 4m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+27.6%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1012 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month